Seeing Is Believing
Currently out of the existing stock ratings of Corey Davis, 1 are a SELL (2.33%), 35 are a BUY (81.4%), 7 are a HOLD (16.28%).
Analyst Corey Davis, currently employed carries an average stock price target met ratio of 71.43% that have a potential upside of 57.54% achieved within 405 days. Previously, Corey Davis worked at LIFESCI.
Corey Davis’s has documented 68 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ZYNE, Zynerba Pharmaceuticals at 15-Aug-2023.
Analyst best performing recommendations are on CARA (CARA THERAPEUTIC).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 10/13/2016. The price target of $20 was fulfilled within 167 days with a profit of $11.91 (147.22%) receiving and performance score of 8.82.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
$1
$0.86 (614.29%)
$2
2 years 7 months 9 days ago
(09-May-2022)
4/5 (80%)
$-0.2 (-16.67%)
77
Hold
$2
$1.86 (1328.57%)
$4
2 years 7 months 9 days ago
(09-May-2022)
7/9 (77.78%)
$0.8 (66.67%)
151
Hold
$1
$0.86 (614.29%)
$3
2 years 7 months 12 days ago
(06-May-2022)
9/17 (52.94%)
$-0.42 (-29.58%)
77
Buy
$11
$10.86 (7757.14%)
$11
2 years 9 months 9 days ago
(09-Mar-2022)
3/6 (50%)
$8.53 (345.34%)
103
Hold
3 years 1 months 13 days ago
(05-Nov-2021)
1/3 (33.33%)
$10.51 (91.47%)
83
What Year was the first public recommendation made by Corey Davis?